Breast cancer Genes
It is estimated that one in eight women, or approximately 12%, will be diagnosed with breast cancer in her lifetime. However, women with certain genetic mutations have a higher lifetime risk of the disease. It’s estimated that 55 – 65% of women with the BRCA1 mutation will develop breast cancer before age 70. Approximately 45% of women with a BRCA2 mutation will develop breast cancer by age 70. Women with a BRCA1 or BRCA2 mutation who overcome their breast cancer with treatment appear to have a higher-than-average chance of developing a second cancer. This is called a recurrence. Cancers related to a BRCA1 mutation are also more likely to be triple negative breast cancer, which can be more aggressive and difficult to treat. You may find these statistics alarming. However, it’s important to note that less than 10% of women diagnosed with breast cancer have a BRCA mutation. Also, with early detection, the vast majority of breast cancer cases can be successfully treated—and that’s true even for people who have a BRCA1 or BRCA2 mutation.
Related Conference of Breast cancer Genes
6th International Conference on Breast Pathology and Cancer Diagnosis
Breast cancer Genes Conference Speakers
Recommended Sessions
- Atypical hyperplasia
- Benign Breast conditions
- Breast Anatomy
- Breast Cancer
- Breast cancer and the Immune system
- Breast cancer control and prevention
- Breast cancer Genes
- Breast cancer in Men
- Breast diseases
- Breast Implants
- Breast microcalcifications
- Ductal carcinoma In Situ
- Lobular carcinoma In Situ
- Surgery for Breast cancer
- Survivorship of Breast cancer
Related Journals
Are you interested in
- Anatomical Pathology - Pathology 2025 (UK)
- Breast Pathology - Pathology 2025 (UK)
- Cancer Pathology - Pathology 2025 (UK)
- Cancer Pathology and Oncology Diagnostics - Pathology Congress-2026 (UAE)
- Cardiovascular Pathology - Pathology Congress-2026 (UAE)
- Clinical Pathology - Pathology 2025 (UK)
- Clinical Pathology and Laboratory Medicine - Pathology Congress-2026 (UAE)
- Cytopathology and Fine Needle Aspiration (FNA) - Pathology Congress-2026 (UAE)
- Cytopathology and Histopathology - Pathology 2025 (UK)
- Dermatopathology - Pathology 2025 (UK)
- Digital Pathology and Artificial Intelligence - Pathology Congress-2026 (UAE)
- Digital Pathology and e-Pathology - Pathology 2025 (UK)
- Environmental and Occupational Pathology - Pathology Congress-2026 (UAE)
- Ethics and Innovations in Pathology - Pathology Congress-2026 (UAE)
- Forensic Pathology and Medical Examinations - Pathology Congress-2026 (UAE)
- Gastrointestinal and Liver Pathology - Pathology 2025 (UK)
- Hematopathology - Pathology 2025 (UK)
- Hematopathology and Blood Disorders - Pathology Congress-2026 (UAE)
- Histopathology and Tissue Engineering - Pathology Congress-2026 (UAE)
- Immunopathology and Autoimmune Diseases - Pathology Congress-2026 (UAE)
- Infectious Disease Pathology - Pathology Congress-2026 (UAE)
- Liver and Gastrointestinal Pathology - Pathology Congress-2026 (UAE)
- Microbial Pathology - Pathology 2025 (UK)
- Molecular Pathology - Pathology 2025 (UK)
- Molecular Pathology and Genomics - Pathology Congress-2026 (UAE)
- Neuropathology and Neurodegenerative Disorders - Pathology Congress-2026 (UAE)
- Oral and Maxillofacial Pathology - Pathology 2025 (UK)
- Pathology Informatics and Data Management - Pathology Congress-2026 (UAE)
- Pediatric Pathology - Pathology Congress-2026 (UAE)
- Renal Pathology - Pathology 2025 (UK)
- Renal Pathology - Pathology Congress-2026 (UAE)
- Surgical Pathology - Pathology 2025 (UK)
- Translational Pathology and Biomarkers - Pathology Congress-2026 (UAE)
- Veterinary Pathology - Pathology 2025 (UK)
- Veterinary Pathology - Pathology Congress-2026 (UAE)